Novo Nordisk (NVO) stock is in focus as the firm gets FDA scrutiny over an Ozempic TV ad, the second warning it received for ...
March 3 (Reuters) - The U.S. Food and Drug Administration has warned Novo Nordisk over a consumer ad for its blockbuster ...
The U.S. Food and Drug Administration (FDA) has issued a warning to Danish pharmaceutical giant Novo Nordisk regarding a consumer advertisement for its widely used diabetes drug, Ozempic. According to ...
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.
Novo Nordisk has agreed to drop its legal case against Hims & Hers and reached a deal for the US telehealth group to sell Novo’s blockbuster weight-loss drugs. Hims’ shares rose 40 per cent on Monday ...
Asianet Newsable on MSN
Novo Nordisk-Hims deal turns Wall Street bullish — BMO sees relief from commercial headwinds, BofA upgrades HIMS stock
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.
March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results